Company news
Laekna, Inc. news in 2026
Laekna, Inc.'s news releases, calls and decks from 2026, newest first.
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
November 5, 2026
Voluntary announcement updates on the 24-week monotherapy study of LAE102 showed promising weight losses favorable changes in body composition and well tolerated safety profile
October 12, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
Interim Report 2026
September 18, 2026
New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration
August 11, 2026